Aim: To expand HBV special interferon-γ secreting human T lymphocytes in vitro and sustain the ability to recognize special T cell epitodes of HBcAg.
Methods: After stimulated by peptide 22 hours, feeded with autologous peripheral blood mononuclear cells ( PBMCs) deproliferated by mitomycin C and low concentration of IL-2 to expand in vitro for other 4 weeks. Then cells were collected and tested by flow cells assay every week. The ability of these cells to recognize special epitodes was tested by enzyme linked immunospot assay in which autologous lymphoblastoid cell lines (LCLs) produced from PBMC was transfected by epstein-barr virus pulsed with peptides and used as target cell.
Results: HBV special interferon-secreting human T lymphocytes were selected and expanded more than 1000 times in vitro. The ability of the T cells to recognize special epitodes is as same as unexpanded cells and the proportion of CD4 and CD8 positive cells likely remained native state.
Conclusion: HBV special interferon-γ secreting T lymphocytes are effectively expanded in vitro and keep the ability to recognize stringently special T cell epotides.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Patient-reported Outcomes in Mothers with Chronic Hepatitis B Infection: A cross-sectional analysis.
Clin Res Hepatol Gastroenterol
January 2025
Department of Infectious Diseases, Key Laboratory of Biological Targeting Diagnosis, Therapy, and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; Division of Gastroenterology and Hepatology, Department of Medicine, NYU Langone Health, New York University Grossman School of Medicine, New York, USA. Electronic address:
Background & Aims: The health-related quality of life (HRQoL) during pregnancy has not been well-lidated in mothers with chronic hepatitis B (CHB). We aim to compare patient-reported outcomes (PROs) in CHB mothers with those of healthy mothers during pregnancy.
Methods: Between 4/16/2023 and 7/31/2023, we invited consecutive CHB and healthy mothers to complete the self-administered 36-item Short Form Survey (SF-36) and the Chronic Liver Disease Questionnaire (CLDQ) for PRO assessment.
Gut microbes associated with functional cure of chronic hepatitis B.
Hepatol Int
January 2025
Department of Virology II, National Institute of Infectious Diseases, Toyama 1-23-1, Shinjuku-ku, Tokyo, 162-8640, Japan.
Background And Aims: Hepatitis B virus (HBV) is prevalent worldwide and is difficult to eradicate. Current treatment strategies for chronic hepatitis B ultimately seek to achieve functional cure (FC); however, the factors contributing to FC remain unclear. We aimed to investigate the gut microbiota profiles of patients with chronic hepatitis B who achieved FC.
View Article and Find Full Text PDFThe Effect of HBV Therapy on Glycemic Control in HBV-Infected Patients With Diabetes: A 90-day Multicenter Study.
J Med Virol
February 2025
Xiangya School of Public Health, Central South University, Changsha, China.
Patients with diabetes are at increased risk of HBV infection; however, the effects of HBV infection and anti-HBV therapy on the management of type 1 diabetes (T1D), type 2 diabetes (T2D), and latent autoimmune diabetes in adults (LADA) remain unclear. From 2016 to 2023, we recruited a multicenter cohort of 355 HBV-infected inpatients, including 136 with T1D, 140 with T2D, and 79 with LADA. The control group included 525 HBV-uninfected inpatients, comparing 171 with T1D, 204 with T2D and 150 with LADA.
View Article and Find Full Text PDFAPOBEC-1 cofactors regulate APOBEC3-induced mutations in hepatitis B virus.
J Virol
January 2025
Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Unlabelled: APOBEC3 proteins (A3s) play an important role in host innate immunity against viruses and DNA mutations in cancer. A3s-induced mutations in both viral and human DNA genomes vary significantly from non-lethal mutations in viruses to localized hypermutations, such as kataegis in cancer. How A3s are regulated remains largely unknown.
View Article and Find Full Text PDFEpigenetic Modifications in HBV-Related Hepatocellular Carcinoma.
J Viral Hepat
February 2025
Medical School, Kunming University of Science and Technology, Kunming, People's Republic of China.
Hepatocellular carcinoma (HCC) is the most common primary liver cancer. Hepatitis B virus (HBV) is the main pathogen for HCC development. HBV covalently closed circular DNA (cccDNA) forms extra-host chromatin-like minichromosomes in the nucleus of hepatocytes with host histones, non-histones, HBV X protein (HBx) and HBV core protein (HBc).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!